APN raises FY 2027 guidance: EBITDA above ZAR 9bn, NHEPS growth over 50%
Aspen Pharmacare (APN) raised FY 2027 guidance, targeting EBITDA over ZAR 9 billion and NHEPS growth above 50%, alongside stronger free cash flow.
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.